Mutations are found in the Ras signal transduction pathway downstream of the receptor in about 90% of patients; thus, JMML belongs to the group of diseases called RASopathies (Noonan syndrome, CBL-syndrome, NF1) [38]. Here, NF1 is linked to Noonan syndrome.